{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=20",
    "query": {
      "intervention": "Matching Oral Placebo",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 3456,
    "total_pages": 346,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T05:02:36.806Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01890746",
      "title": "A Safety and Efficacy Study of Eltrombopag in Subjects With AML",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Leukaemia"
      ],
      "interventions": [
        {
          "name": "Daunorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Eltrombopag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 148,
      "start_date": "2013-09-05",
      "completion_date": "2017-01-25",
      "has_results": true,
      "last_update_posted_date": "2019-09-11",
      "last_synced_at": "2026-10-15T05:02:36.806Z",
      "location_count": 14,
      "location_summary": "Farmington, Connecticut • Miami, Florida • Orlando, Florida + 11 more",
      "locations": [
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Ames",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01890746"
    },
    {
      "nct_id": "NCT02511886",
      "title": "A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Use Disorder"
      ],
      "interventions": [
        {
          "name": "Arbaclofen Placarbil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indivior Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 18,
      "start_date": "2015-09",
      "completion_date": "2016-01",
      "has_results": false,
      "last_update_posted_date": "2017-01-23",
      "last_synced_at": "2026-10-15T05:02:36.806Z",
      "location_count": 1,
      "location_summary": "Oakland Park, Florida",
      "locations": [
        {
          "city": "Oakland Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02511886"
    },
    {
      "nct_id": "NCT05175105",
      "title": "A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pediatric Pyruvate Kinase Deficiency",
        "Pediatric Hemolytic Anemia"
      ],
      "interventions": [
        {
          "name": "Mitapivat",
          "type": "DRUG"
        },
        {
          "name": "Mitapivat-matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agios Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 30,
      "start_date": "2022-06-06",
      "completion_date": "2030-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-10-15T05:02:36.806Z",
      "location_count": 11,
      "location_summary": "Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05175105"
    },
    {
      "nct_id": "NCT04749745",
      "title": "Effects of L-theanine on Motor Cortex Excitability in Healthy Subjects: A Paired-Pulse TMS Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Cortical Excitability",
        "Psychiatric Disorder"
      ],
      "interventions": [
        {
          "name": "L-theanine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Butler Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 11,
      "start_date": "2020-06-09",
      "completion_date": "2021-05-31",
      "has_results": true,
      "last_update_posted_date": "2021-09-23",
      "last_synced_at": "2026-10-15T05:02:36.806Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04749745"
    },
    {
      "nct_id": "NCT00251680",
      "title": "Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Lapaquistat acetate and lipid-lowering therapy",
          "type": "DRUG"
        },
        {
          "name": "Lipid-lowering therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2005-10",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2012-05-24",
      "last_synced_at": "2026-10-15T05:02:36.806Z",
      "location_count": 18,
      "location_summary": "Tucson, Arizona • Artesia, California • Jacksonville, Florida + 15 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Dunwoody",
          "state": "Georgia"
        },
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00251680"
    },
    {
      "nct_id": "NCT03829241",
      "title": "Randomized Trial of Adult Participants With Generalized Anxiety Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Generalized Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "Troriluzole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biohaven Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 881,
      "start_date": "2019-02-19",
      "completion_date": "2020-05-08",
      "has_results": true,
      "last_update_posted_date": "2024-05-08",
      "last_synced_at": "2026-10-15T05:02:36.806Z",
      "location_count": 53,
      "location_summary": "Little Rock, Arkansas • Colton, California • Encino, California + 48 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03829241"
    },
    {
      "nct_id": "NCT06280235",
      "title": "A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "BI 1569912",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 243,
      "start_date": "2024-03-27",
      "completion_date": "2025-03-28",
      "has_results": true,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-10-15T05:02:36.806Z",
      "location_count": 21,
      "location_summary": "Tucson, Arizona • Oceanside, California • Orange, California + 17 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Panorama City",
          "state": "California"
        },
        {
          "city": "Cromwell",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06280235"
    },
    {
      "nct_id": "NCT04472832",
      "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Placebo for Treatment A",
          "type": "DRUG"
        },
        {
          "name": "Mitapivat 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Treatment B",
          "type": "DRUG"
        },
        {
          "name": "Mitapivat 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Treatment C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agios Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2020-06-17",
      "completion_date": "2020-11-23",
      "has_results": false,
      "last_update_posted_date": "2021-02-18",
      "last_synced_at": "2026-10-15T05:02:36.806Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04472832"
    },
    {
      "nct_id": "NCT01282684",
      "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PLX5622",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Plexxikon",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2011-01",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2015-03-30",
      "last_synced_at": "2026-10-15T05:02:36.806Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01282684"
    },
    {
      "nct_id": "NCT03650452",
      "title": "A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epilepsy",
        "Dravet Syndrome",
        "Lennox-Gastaut Syndrome"
      ],
      "interventions": [
        {
          "name": "TAK-935",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 141,
      "start_date": "2018-08-08",
      "completion_date": "2020-07-20",
      "has_results": true,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-15T05:02:36.806Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03650452"
    }
  ]
}